Table 2

 Trends of secondary outcome measures in the two groups and results of two way analysis of variance for the strength of the cumulative “time × treatment” effect

STN-SControlsTime × treatment p value
Time point (no of cases)T0 (23)T12 (23)T24 (13)T0 (16)T12 (13)T24 (8)T12T24
BDI, Beck Depression Inventory; LEDD, levodopa equivalent daily dose; NS, not significant; UPDRS-III, Unified Parkinson’s Disease Rating Scale Motor section.
UPDRS-III OFF (mean (SD))38.3 (11.6)17.9 (11.7)18.0 (4.7)37.4 (5.1)39.8 (6.3)41.7 (7.9)<0.00000.001
UPDRS-III ON (mean (SD))10.2 (8.2)11.7 (8.7)13.5 (8.5)12 (9.2)13 (5.4)14 (5.8)NSNS
OFF daily rate mean ((SD))46.1 (1.8)5.9 (6.4)5.2 (6.3)38.1 (15.5)42.1 (4.6)45.8 (8.9)<0.00000.0001
Rate of dyskinesia (median (quartiles))2 (1–3)0 (0–1)0 (0–1)1 (1–2)2 (1–2)2 (1–3)0.000080.01
Drooling (median (quartiles))0 (0–1)0 (0–1)1 (0–1)0 (0–1)0 (0–1)1 (0–1)NSNS
Speech (median (quartiles))2 (1–2)1 (0–2)2 (1–3)0 (0–1)0 (0–1)1 (0–2)NSNS
Tremor (median (quartiles))2 (1–3)0 (0–1)0 (0–1)1 (1–2)1 (1–2)2 (1–2)0.00010.001
Gait (median (quartiles))2 (1–2)1 (0–1)1(1–2)1 (1–2)2 (1–2)2 (1–2)0.010.05
Freezing (median (quartiles))2 (0–3)1 (0–2)1 (1–2)1 (1–2)2 (1–2)1 (1–2)0.04NS
Postural reflex (median (quartiles))2 (1–2)1 (0–2)1 (1–2)1 (0–1)1 (0–2)1 (0–2)0.0070.007
Falls (median (quartiles))0 (0–1)0 (0–0)0 (0–0)0 (0–1)0 (0–0)1 (0–1)0.05NS
Sensory symptoms (median (quartiles))2 (1–2)0 (0–0)0 (0–1)1 (1–2)2 (1–3)2 (1–2)0.00010.001
LEDD (mean (SD))987.87 (427.0)708.0 (311.0)561.0 (347.0)961.19 (474.0)1032.4 (356.6)922.5 (289.1)0.00050.05
BDI (mean (SD))14.4 (6.9)9.5 (2.6)9.5 (4.1)13.5 (6.4)10.5 (4.9)8.5 (4.9)NSNS